GET DAILY SIGNALSAligos Therapeutics (ALGS) Drops -61% in 30 Days as Cash Runway Shortens
Key Takeaways
- Aligos Therapeutics (ALGS) shares fell roughly 61% over the past 30 days, dropping from about $5.23 to near $2.03, one of the sharpest declines among small-cap biotechs in the period.
- The selloff accelerated after third-quarter 2026 results, when management disclosed a cash position of $31.1 million expected to fund operations only through early 2027.
- That short runway triggered a going-concern warning, which overshadowed a better-than-expected earnings-per-share result and positive hepatitis data presented at a major liver-disease conference.
- Over the trailing quarter, ALGS has declined about 70%, giving back a sharp rally that had carried the stock above $7 in early August.
- Analyst consensus remains "Strong Buy," but near-term sentiment is dominated by funding and potential dilution risk rather than clinical progress.
- For additional context, review ALGS price targets, earnings, and forecast pages.
Company Background and Pipeline Focus
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company develops novel therapeutics for liver and viral diseases with high unmet medical need, including chronic hepatitis B (HBV), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.
Its pipeline includes pevifoscorvir sodium, a capsid assembly modulator in a Phase 2b study for chronic HBV; ALG-055009, a small-molecule THR-β agonist in Phase 2a development for MASH and obesity; and ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor that has completed a Phase 1 trial. The company has no approved products and generates limited revenue, so investors follow ALGS primarily for clinical data catalysts, cash runway, and partnership activity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALGS fell approximately 61%, declining from a closing price of $5.23 on October 14, 2026, to roughly $2.03 in the most recent session. The decline steepened sharply in early November, with the stock losing more than half its value in the span of about a week following its third-quarter earnings report.
The quarterly picture is even steeper. From a close of about $6.77 in mid-August, ALGS has dropped roughly 70%. The stock had rallied strongly in early August to an intraday high above $7.60, but those gains unwound steadily through September and October before the November slide accelerated the downtrend. The overall trajectory reflects a decisive shift from optimism around clinical progress toward concern about the company's balance sheet.
What Drove the Stock in the Last 30 Days
The primary catalyst was Aligos' third-quarter 2026 update, released November 6, 2026. The company reported a net loss of $2.09 per share, narrower than the roughly $2.28 consensus estimate, and revenue of about $2.87 million. However, revenue came in below analyst expectations, and — more importantly — management disclosed that its cash, cash equivalents, and investments of $31.1 million as of September 30, 2026, are expected to fund operations only through the first quarter of 2027.
That limited runway prompted a going-concern disclosure, a signal for clinical-stage companies that additional capital will likely be required to continue as planned. For existing shareholders, that raises the prospect of dilutive financing or program curtailment, and the market repriced the stock quickly and sharply. The decline occurred even as Aligos presented what it characterized as positive hepatitis B and hepatitis D data at The Liver Meeting 2026 and announced completion of enrollment in its Phase 2b B-SUPREME study. In this environment, the funding overhang outweighed the clinical news. From what I see, this balance-sheet focus often overrides other developments in the near term.
Quarterly Trends and the Broader Reversal
The broader three-month trend reflects a reversal of an early-August rally. Aligos shares spiked above $7.60 in early August, likely on momentum following its second-quarter 2026 report and clinical updates, before steadily fading as investors reassessed the company's cash position and the long timeline to its next major data readout. The Phase 2b B-SUPREME topline results are not expected until late 2027, leaving a prolonged period with limited near-term clinical catalysts.
The November going-concern disclosure converted that gradual decline into an abrupt repricing, as markets shifted focus from scientific merit to financing durability. A rising-rate backdrop, which raises the discount applied to distant cash flows and makes dilutive financings costlier, compounded pressure on this pre-revenue biotech.
Looking Ahead at Key Drivers
The most important factor ahead is how and when Aligos addresses its funding gap. Any financing announcement, partnership, or restructuring will be scrutinized for its impact on existing shareholders. Investors will also watch for further updates on the Phase 2b B-SUPREME study of pevifoscorvir sodium in chronic HBV, with topline data expected in late 2027, as well as progress from ALG-055009 in MASH and obesity and from partner Amoytop's Phase 1 advancement of ALG-170675 in China. Macroeconomic conditions, particularly the interest-rate environment and overall biotech risk appetite, will continue to influence sentiment for cash-burning, development-stage companies. These factors carry both opportunity and risk, and none constitute a guarantee of future performance. I’m watching this closely for any signs of resolution on the financing front.
Exploring AI Trading Bots for Biotech Exposure
In my own process, I sometimes review Tickeron’s AI Trading Bots to test systematic approaches across volatile names like ALGS. The platform offers a range of strategies with different timeframes and risk parameters, which can help compare options without relying solely on discretionary calls. It serves as one more data point when evaluating how market moves might play out in a sector sensitive to both clinical updates and capital needs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Momentum Indicator for ALGS turns negative, indicating new downward trend
ALGS saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 83 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALGS entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.498). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement